Myeloproliferative Disorders (MPD) Treatment Market Size Outlook, Share and Growth and Forecast Assumptions 2022-2031

The global myeloproliferative disorders drug market is anticipated to grow significantly during the forecast period due to the increasing prevalence of the various myeloproliferative disorders, the presence of strong pipeline products, frequent product approvals, and growing R&D investments on the development of novel drugs for MPD Treatment market.

According to the National Organization for Rare Disorders (NORD), men are more likely affected than women with Polycythemia vera. The disorder is anticipated to affect around two people per 100,000 in the general population. It occurs most often in individuals over 60 years old but can affect individuals of any age.

However, side effects associated with chemotherapy medications might hamper the growth of the market studied.

Get a PDF Sample for more detailed market insights: https://www.sdki.us/sample-request-89210

Key Market Trends

Myelofibrosis Segment Holds Significant Share in the MPD Treatment Market


Myelofibrosis is a group of rare cancers of bone marrow in which the marrow is replaced by scar tissue and cannot make healthy blood cells. It is classified as a type of chronic leukemia and belongs to a group of blood disorders called myeloproliferative diseases. It is also called as primary myelofibrosis, chronic idiopathic myelofibrosis or myelosclerosis with myeloid metaplasia.

According to the National Organization for Rare Disorders (NORD), the true incidence of MF is not known but estimated to be approximately 1-1.5 per 100,000 people and is likely higher due to under-diagnosing and under-reporting.

Frequent product launches of the drugs for myelofibrosis treatment are expected to drive the segment in the market studied. For instance, in September 2019, Sierra Oncology Inc. received U.S. Food and Drug Administration (FDA) Fast Track designation approval to its momelotinib, a JAK1, JAK2 and ACVR1 inhibitor for the treatment of patients with intermediate/high-risk myelofibrosis who have previously received a JAK inhibitor.

North America Dominates the Global Myeloproliferative Disorders Treatment Market

North America dominates the global MPD treatment market owing to the increase in the prevalence of myelodysplastic syndrome, early adoption of the novel treatments, high R&D investments on the development of the novel drugs, and the presence of sophisticated healthcare infrastructure.

For instance, in August 2019, Celgene Corporation (Acquired by Bristol-Myers Squibb) received U.S. Food and Drug Administration (FDA) approval to its INREBIC (fedratinib) for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.

The Asia Pacific is expected to experience lucrative growth in the global myeloproliferative disorders treatment market due to the developing healthcare infrastructure, rapidly improving economic conditions, and promising regulatory environment for new treatment.

Myeloproliferative Disorders (MPD) Treatment Market Size Outlook, Share and Growth and Forecast Assumptions 2022-2031
Muscle Relaxant Drugs Market Size Insight & Future Assessment for the Period 2022-2031
North America Enhanced Oil Recovery Market Size Inclinations & Development Status Highlighted During Forecast Period 2022-2031
Middle East & Africa Oil & Gas Subsea Umbilicals, Risers and Flowlines (SURF) Market Size Drivers and Key Players Strategies Analyzed 2022-2031
Middle East & Africa Oil & Gas Pipeline Market Size: Industry Development Scenario and Forecast 2022-2031
Middle East & Africa Oil & Gas Pipeline Leak and Theft Detection Market Size Analysis Covering Share, Growth, Trends and Upcoming Opportunities 2022-2031
Middle East & Africa Enhanced Oil Recovery Market Size Qualitative Insights on Application & Outlook By Share, Future Growth and Forecast 2022-2031

Leave a Reply

Your email address will not be published. Required fields are marked *